Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Alvesco Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG105

    Alvesco (ciclesonide)

    Customize your policy alerts

    Sign up for Oscar Health Policy PG105 alerts

    Get alerted when Policy PG105 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity review for Alvesco (ciclesonide) inhalation used for asthma maintenance therapy, including initial and continued therapy reviews.

    Policy Summary
    PayerOscar Health
    PolicyAlvesco (ciclesonide)
    Policy CodePolicy PG105
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 4, 202747d
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that the member meets all applicable medical necessity criteria for Alvesco.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12+Minimum age for covered use
    3Required formulary alternatives
    12 monthsMaximum approval duration
    Asthma maintenanceCovered use
    80–320 mcg BIDAppendix dosage range

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy for asthma

    Covered when ALL of the following are met:

    Initial asthma therapy criteria

    • Member and diagnosis

      • The member is 12 years of age or older.Age ≥ 12 years
      • The member has a documented diagnosis of asthma.
    • Indication and formulary alternatives

      • The requested product is being used as preventive therapy for asthma maintenance control.
      • The member is unable to use, or has tried and failed, all of the following formulary alternatives: Arnuity Ellipta (fluticasone furoate), fluticasone propionate (Flovent), and QVAR (beclomethasone dipropionate).All 3 alternatives

        Failure may include lack of symptom control, adverse effects, or intolerance.

    • Dosing

      • Alvesco (ciclesonide) is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.FDA-labeled or evidence-supported dose and frequency

    Continuation therapy for asthma

    Covered when ALL of the following are met:

    Continuation asthma therapy criteria

    • The member meets the applicable initial clinical review criteria.Applicable initial criteria met
    • ONE of the following therapeutic response outcomes

      • Chart documentation shows clinical improvement in symptoms since starting the requested medication.
      • Chart documentation shows disease stability since starting the requested medication.

    Alvesco (ciclesonide) is not indicated for relief of acute bronchospasms. Coverage is limited to preventive maintenance treatment of asthma.

    Use of Alvesco in members younger than 12 years is not covered under the medical necessity criteria. The covered indication applies to preventive asthma maintenance therapy in members 12 years of age and older.

    Prior Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required. Alvesco will be approved for up to 12 months when all applicable initial medical necessity criteria are met.

    • Member is 12 years of age or older.
    • Documented diagnosis of asthma.
    • Requested use is preventative therapy for asthma maintenance control.
    • Requested dose and frequency are within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines.
    Prior Authorization

    Continuation Prior Authorization Required

    Continuation prior authorization is required. Renewal approval is available for up to 12 months when the member continues to meet the applicable initial criteria and documentation demonstrates therapeutic response.

    • Submit the applicable initial clinical review criteria with the continuation request.
    • Document clinical improvement in symptoms or disease stability since starting Alvesco.

    Clinical Background

    Asthma is a chronic inflammatory airway disease characterized by recurrent wheezing, breathlessness, chest tightness, and coughing. Airway inflammation can cause hypersensitivity and constriction in response to triggers such as allergens, pollutants, and respiratory infections. Inhaled corticosteroid-containing therapy reduces the frequency and severity of symptoms and lowers the risk of exacerbations and asthma-related death. Alvesco (ciclesonide) is FDA approved as prophylactic maintenance treatment for adults and pediatric patients 12 years of age and older; it is not intended for acute bronchospasm relief.

    Definitions

    Allergy
    DefinitionHaving allergen-specific IgE and developing symptoms when exposed to substances containing that allergen.
    Immune markerAllergen-specific IgE is associated with the allergic response.
    Exposure requirementSymptoms occur after exposure to a substance containing the relevant allergen.
    Anaphylaxis
    DefinitionA severe, systemic immune response that may affect more than one organ system.
    Possible symptomsMay include flushing, trouble breathing, vomiting or diarrhea, mouth or throat swelling, and rash.
    Urgency

    Initial Alvesco Therapy

    Initial Alvesco therapy for asthma

    Covered when ALL of the following are met:

    Initial Alvesco criteria

    • The member is 12 years of age or older and has a documented diagnosis of asthma.Age ≥ 12 years
    • The requested product is being used as preventive therapy for asthma maintenance control.
    • The member is unable to use, or has tried and failed, all of the following formulary alternatives: Arnuity Ellipta (fluticasone furoate), fluticasone propionate (Flovent), and QVAR (beclomethasone dipropionate).All 3 alternatives

      Failure may include lack of symptom control, adverse effects, or intolerance.

    Continued Alvesco Therapy

    Continued Alvesco therapy

    Covered when ALL of the following are met:

    Continuation criteria

    • The member meets the applicable initial clinical review criteria.Applicable initial criteria met
    • ONE of the following therapeutic response outcomes

      • Chart documentation shows clinical improvement in symptoms since starting Alvesco.
      • Chart documentation shows disease stability since starting Alvesco.

    Required Formulary Alternatives

    StepRequired formulary alternativesQualifying requirement
    1Arnuity Ellipta (fluticasone furoate); fluticasone propionate (Flovent); and QVAR (beclomethasone dipropionate)The member must be unable to use or have tried and failed all listed alternatives. Failure may include lack of symptom control, adverse effects, or intolerance.
    Policy Summary
    PayerOscar Health
    PolicyAlvesco (ciclesonide)
    Policy CodePolicy PG105
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 4, 202747d
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that the member meets all applicable medical necessity criteria for Alvesco.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider RequirementsClinical BackgroundDefinitionsInitial Alvesco TherapyContinued Alvesco TherapyRequired Formulary Alternatives
    Step Therapy

    Required Formulary Alternatives

    Before requesting Alvesco, document that the member is unable to use or has tried and failed all listed formulary alternatives.

    • Arnuity Ellipta (fluticasone furoate).
    • Fluticasone propionate (Flovent).
    • QVAR (beclomethasone dipropionate).
    • Document lack of symptom control, adverse effects, intolerance, or another applicable reason for each alternative.
    Documentation Required

    Initial Review Documentation

    Submit documentation supporting the asthma diagnosis and the requested maintenance therapy.

    • Up-to-date chart notes, relevant test results, and/or relevant imaging reports supporting the diagnosis.
    • Documentation that Alvesco is being requested for preventative asthma maintenance control.
    • Prescription claims records and/or receipts supporting prior trials of formulary alternatives, when applicable.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, submit chart documentation showing that the member has experienced a therapeutic response to Alvesco.

    • Progress notes, spirometry results, or patient-reported outcomes may be used.
    • Document clinical improvement in symptoms or disease stability since treatment began.
    Denial Risk

    Initial Criteria and Noncovered-Use Denial Risks

    Coverage may be denied when the requested use is outside the covered indication or when initial medical necessity requirements are not met.

    • Member is younger than 12 years of age.
    • Asthma diagnosis is not documented.
    • Alvesco is requested for acute bronchospasm relief rather than preventative maintenance control.
    • Required formulary alternatives have not all been tried and failed or cannot be used.
    • Requested dose or frequency is not within FDA-approved labeling and lacks compendia or evidence-based published support.
    Denial Risk

    Insufficient Response for Continuation

    Continuation approval may be denied when the member does not meet the applicable continuation criteria or the request lacks adequate evidence of therapeutic response.

    • Applicable initial clinical review criteria are not met.
    • Documentation does not show clinical improvement in symptoms or disease stability since starting Alvesco.
    • Required progress notes, spirometry results, or patient-reported outcomes are not submitted.
    Denial Risk

    Other Uses Are Unproven

    Other uses are unproven. Alvesco (ciclesonide) for any use other than covered asthma maintenance therapy is considered experimental, investigational, or unproven.

    • Do not request coverage for indications outside preventative asthma maintenance control without applicable supporting policy criteria.
    Anaphylaxis can be rapidly fatal without immediate treatment.
    Documentation
    DefinitionWritten information used to support diagnoses and prior trials of formulary alternatives.
    Clinical recordsIncludes up-to-date chart notes, relevant test results, and relevant imaging reports supporting diagnoses.
    Prescription historyIncludes prescription claims records or prescription receipts supporting prior trials of formulary alternatives.
    Exacerbation / Flare-up
    DefinitionA worsening or increase in the severity of a disease or its signs and symptoms.
    Asthma featuresIn asthma, this may involve worsening shortness of breath, coughing, wheezing, chest tightness, or lung function compared with the individual's usual condition.
    Typical consequenceAn exacerbation often requires additional medication or healthcare intervention.
    Trigger
    DefinitionA stimulus that may worsen or increase asthma symptoms or airflow limitation.
    Common triggersTriggers may include allergens, respiratory infections, exercise, stress, and air pollution.
    IrritantsExposure to irritants such as tobacco smoke may also trigger symptoms or airflow limitation.
    Alvesco (ciclesonide) is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.FDA-labeled or evidence-supported dose and frequency